drugset / Trial / NCT00688831

Single Ascending Dose Study (SAD) iv Formulation

NCT00688831

Phase 1 Completed 36 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

Timeline

Start
2008-01
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule Intravenous

Indications

No indication recorded.